FBFriederike Berberich-Siebelt

Friederike Berberich-Siebelt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Friederike Berberich-Siebelt has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-redundant functions of NFATc1 in survival and NFATc2 in generation of exhausted CD8+ T cells

    by Salvador Sampere-Birlanga, Stefan Klein-Hessling, Miriam Campillo Prados, Anfei Huang, Hao Wu, Andreas Rosenwald, Wolfgang Kastenmüller, Edgar Serfling, Martin Vaeth, Friederike Berberich-Siebelt

    Persistent antigenic stimulation leads to the dysfunction of CD8 + cytotoxic T cells. These “exhausted” T EX cells exhibit reduced proliferative capacity, impaired effector function, and increased expression of co-inhibitory receptors. Chronic antigen receptor stimulation induces the expression of NFATc1/αA, a short isoform of NFATc1 that promotes T EX cell survival. The induction of NFATc1/αA is accompanied by a significant decrease in NFATc2 expression. NFATc2 limits the expression of stemness-associated genes, such as Tcf7 , Sell , and Id3. It also supports the expression of Prf1 , Gzmb , and the T EX marker gene Havcr2 . Therefore, ablation of NFATc2 mitigates functional exhaustion of CD8 + T cells during chronic viral infection and antitumor immunity. Our findings illustrate that NFATc1 promotes the survival of T EX cells, while NFATc2 promotes the terminal differentiation and dysfunction of exhausted CD8 + T cells. The data suggest a non-redundant interplay between NFATc1 and NFATc2, each playing a distinct role in controlling CD8 + T-cell exhaustion. These findings open novel avenues to enhance the efficacy of immune checkpoint and CAR T-cell therapies.

  • Open Access

    Cytotoxic CD4+ T-follicular cells may mediate killing against lymphoma cells

    by Yin Xiao, Sigrun S. Haeusl, Gaurav Jethva, Johannes Weber, Andreas Rosenwald, Friederike Berberich-Siebelt

    Recently, we have identified CD4+PD-1+CXCR5+ T-follicular helper (TFH) cells with a distinct cytotoxic phenotype and named them “killer TFH (TFK)” cells. In this study, we aim to elucidate their presence and functional relevance in two different lymphoma subtypes, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Flow cytometric analysis of tonsillar versus FL-cell suspensions revealed a heightened number of GZMK+NKG7/TIA-1+ TFK cells in the latter, accompanied by a significant increase in T-regulatory and T-follicular regulatory (TFR) cells. In contrast, DLBCL exhibited a decrease in TFH and TFR cell numbers, while concurrently demonstrating heightened frequencies of GZMK+TIA-1+ and especially GZMB+TIA-1+ TFK cells within the TFH population. Analysis of single-cell RNA sequencing data confirmed an origin-specific phenotype of TFK cells. Immunofluorescence staining of biopsy specimens detected CD4+BCL-6+TIA-1+ TFK cells within follicles and germinal centers (GC) in reactive lymph nodes and within their atypical counterparts in malignant lymph nodes. Their propensity to migrate into atypical GCs was more pronounced in higher grade FLs. Furthermore, the release of cytotoxic cargo by degranulation could be induced by stimulation of CD4+ cells in cultures of FL and DLBCL suspensions. In line, the direct cytotoxic capacity of TFK cells against lymphoma cells was demonstrated by killing assays with isolated cells, underscoring their potential as a prospective therapeutic target in lymphoma control.


  • Open Access

    NFAT single-deficient murine T cells reduce the risk of aGvHD while controlling cytomegalovirus infection

    by Nadine Hundhausen, Snigdha Majumder, Yin Xiao, Sigrun S. Haeusl, Helen Goehler, Rishav Seal, Cristina M. Chiarolla, Andreas Rosenwald, Matthias Eyrich, Luka Cicin-Sain, et al.


  • Open Access

    Oligoclonal CD4+CXCR5+ T cells with a cytotoxic phenotype appear in tonsils and blood

    by Chunguang Liang, Silvia Spoerl, Yin Xiao, Katharina M. Habenicht, Sigrun S. Haeusl, Isabel Sandner, Julia Winkler, Nicholas Strieder, Rüdiger Eder, Hanna Stanewsky, et al.

    In clinical situations, peripheral blood accessible CD3+CD4+CXCR5+ T-follicular helper (TFH) cells may have to serve as a surrogate indicator for dysregulated germinal center responses in tissues. To determine the heterogeneity of TFH cells in peripheral blood versus tonsils, CD3+CD4+CD45RA–CXCR5+ cells of both origins were sorted. Transcriptomes, TCR repertoires and cell-surface protein expression were analysed by single-cell RNA sequencing, flow cytometry and immunohistochemistry. Reassuringly, all blood-circulating CD3+CD4+CXCR5+ T-cell subpopulations also appear in tonsils, there with some supplementary TFH characteristics, while peripheral blood-derived TFH cells display markers of proliferation and migration. Three further subsets of TFH cells, however, with bona fide T-follicular gene expression patterns, are exclusively found in tonsils. One additional, distinct and oligoclonal CD4+CXCR5+ subpopulation presents pronounced cytotoxic properties. Those ‘killer TFH (TFK) cells’ can be discovered in peripheral blood as well as among tonsillar cells but are located predominantly outside of germinal centers. They appear terminally differentiated and can be distinguished from all other TFH subsets by expression of NKG7 (TIA-1), granzymes, perforin, CCL5, CCR5, EOMES, CRTAM and CX3CR1. All in all, this study provides data for detailed CD4+CXCR5+ T-cell assessment of clinically available blood samples and extrapolation possibilities to their tonsil counterparts.


  • Open Access

    Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis

    by Rishav Seal, Lara S. U. Schwab, Cristina M. Chiarolla, Nadine Hundhausen, Georg Heinrich Klose, Simone Reu-Hofer, Andreas Rosenwald, Johannes Wiest, Friederike Berberich-Siebelt

    In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.


  • Open Access

    Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies

    by Martina Seefried, Nadine Hundhausen, Irena Kroeger, Maike Büttner-Herold, Petra Hoffmann, Matthias Edinger, Evelyn Ullrich, Friederike Berberich-Siebelt, William J. Britt, Michael Mach, et al.

    Reactivation of human cytomegalovirus (HCMV) from latency is a frequent complication following hematopoietic stem cell transplantation (HSCT). The development of acute graft-versus-host disease (GVHD) is a significant risk factor for HCMV disease. Using a murine GVHD model in animals latently infected with murine CMV (MCMV), we studied preventive and therapeutic interventions in this high-risk scenario of HSCT. Mice latently infected with MCMV experienced reactivated MCMV and developed disseminated MCMV infection concomitant with the manifestations of GVHD. Dissemination was accompanied by accelerated mortality. We demonstrate that MCMV reactivation and dissemination was modulated by MCMV-specific antibodies, thus demonstrating in vivo protective activity of antiviral antibodies. However, the efficacy of serum therapy required repetitive doses of high-titer immune serum secondary to the shortened serum half-life of IgG in animals with GVHD. In a complementary approach, treatment of GVHD by adoptive transfer of donor-derived Tregs facilitated production of MCMV-specific antibodies from newly developing donor-derived B cells. Together, our findings strongly suggest that antibodies play a major role in controlling recurrent MCMV infection that follows GVHD, and they argue for reassessing the potential of antibody treatments as well as therapeutic strategies that enhance de novo antibody development against HCMV.


  • Open Access

    Pro-inflammatory innate-like T cells are expanded in the blood and inflamed intestine in Crohn’s Disease

    by Cristina M. Chiarolla, Axel R. Schulz, Michael Meir, Simone Reu-Hofer, Addi J. Romero-Olmedo, Michael Lohoff, Andreas Rosenwald, Hyun-Dong Chang, Nicolas Schlegel, Henrik E. Mei, et al.

    A complex and tissue-specific network of cells including T lymphocytes maintains intestinal homeostasis. To address disease and tissue-specific alterations, we performed a T cell-centric mass cytometry analysis of peripheral and intestinal lymphocytes from patients with Crohn’s disease (CD) and healthy donor PBMCs. We compared inflamed and not inflamed tissue areas of bowel resections. Chronic inflammation enforced activation, exhaustion and terminal differentiation of CD4 + and CD8 + T cells and an enrichment of CD4 + Foxp3 + cells (Tregs) in inflamed intestine. However, tissue-repairing Tregs decreased, while enigmatic rare Foxp3 + T-cell subsets appeared upon inflammation. In vitro assays revealed that those subsets, e.g. CD4 + Foxp3 + HLA-DR + TIGIT − and CD4 + Foxp3 + CD56 + , express pro-inflammatory IFN-γ. Some T-conventional (Tcon) cells tended towards innateness. In blood of CD patients, not well studied CD4 + and CD8 + subsets of CD16 + CCR6 + CD127 + T cells appeared anew, a phenotype reproducible by incubation of healthy blood T cells with patient blood plasma. Together, these findings suggest a bias towards innate-like pro-inflammatory Tregs and innate-like Tcon, which act with less specific cytotoxicity. Most likely, this is both cause and consequence of intestinal inflammation during CD. Graphical

  • Open Access

    NFATc1/αA and Blimp-1 Support the Follicular and Effector Phenotype of Tregs

    by Anika Koenig, Martin Vaeth, Yin Xiao, Cristina M. Chiarolla, Raghu Erapaneedi, Matthias Klein, Lena Dietz, Nadine Hundhausen, Snigdha Majumder, Felix Schuessler, et al.

    CD4+CXCR5+Foxp3+ T-follicular regulatory (TFR) cells control the germinal center responses. Like T-follicular helper cells, they express high levels of Nuclear Factor of Activated T-cells c1, predominantly its short isoform NFATc1/αA. Ablation of NFATc1 in Tregs prevents upregulation of CXCR5 and migration of TFR cells into B-cell follicles. By contrast, constitutive active NFATc1/αA defines the surface density of CXCR5, whose level determines how deep a TFR migrates into the GC and how effectively it controls antibody production. As one type of effector Treg, TFR cells express B lymphocyte-induced maturation protein-1 (Blimp-1). Blimp-1 can directly repress Cxcr5 and NFATc1/αA is necessary to overcome this Blimp-1-mediated repression. Interestingly, Blimp-1 even reinforces the recruitment of NFATc1 to Cxcr5 by protein-protein interaction and by those means cooperates with NFATc1 for Cxcr5 transactivation. On the contrary, Blimp-1 is necessary to counterbalance NFATc1/αA and preserve the Treg identity. This is because although NFATc1/αA strengthens the follicular development of Tregs, it bears the inherent risk of causing an ex-Treg phenotype.


  • Open Access

    Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells

    by Snigdha Majumder, Isabelle Jugovic, Domenica Saul, Luisa Bell, Nadine Hundhausen, Rishav Seal, Andreas Beilhack, Andreas Rosenwald, Dimitrios Mougiakakos, Friederike Berberich-Siebelt

    Gene editing of primary T cells is a difficult task. However, it is important for research and especially for clinical T-cell transfers. CRISPR/Cas9 is the most powerful gene-editing technique. It has to be applied to cells by either retroviral transduction or electroporation of ribonucleoprotein complexes. Only the latter is possible with resting T cells. Here, we make use of Cas9 transgenic mice and demonstrate nucleofection of pre-stimulated and, importantly, of naive CD3+ T cells with guideRNA only. This proved to be rapid and efficient with no need of further selection. In the mixture of Cas9+CD3+ T cells, CD4+ and CD8+ conventional as well as regulatory T cells were targeted concurrently. IL-7 supported survival and naivety in vitro, but T cells were also transplantable immediately after nucleofection and elicited their function like unprocessed T cells. Accordingly, metabolic reprogramming reached normal levels within days. In a major mismatch model of GvHD, not only ablation of NFATc1 and/or NFATc2, but also of the NFAT-target gene IRF4 in naïve primary murine Cas9+CD3+ T cells by gRNA-only nucleofection ameliorated GvHD. However, pre-activated murine T cells could not achieve long-term protection from GvHD upon single NFATc1 or NFATc2 knockout. This emphasizes the necessity of gene-editing and transferring unstimulated human T cells during allogenic hematopoietic stem cell transplantation.


  • The extreme C-terminus of IRAK2 assures full TRAF6 ubiquitination and optimal TLR signaling

    by Hemant Joshi, Benjamin Lunz, Andrea Peters, Michael Zölch, Ingolf Berberich, Friederike Berberich-Siebelt